Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets

PTI New Delhi | Updated on July 20, 2020

The drug is used for treatment of secondary hyperparathyroidism for chronic kidney disease

Drug major Cipla on Monday said it has reached a settlement with Amgen Inc on pending litigation involving generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease.

“The civil action filed by Cipla Ltd and Cipla USA Inc, wholly owned step-down subsidiary of Cipla Ltd (hereinafter together referred to as Cipla), in the US District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc,” Cipla said in a regulatory filing.

A formal stipulation of dismissal has been filed with the court and and the signature by the presiding Judge is awaited, the filing added.

It further said “the resolution entitles Cipla and its affiliates to continue importing, marketing, and selling their generic cinacalcet hydrochloride tablets in the United States”.

Cipla’s cinacalcet hydrochloride tablets, in the strengths of 30mg, 60mg and 90mg, are generic versions of Sensipar, a branded drug marketed by Amgen Inc.

Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Shares of Cipla were trading 1.43 per cent lower at ₹679.75 apiece on the BSE.

Published on July 20, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like